|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D055371||Acute Lung Injury NIH||0.09|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.08|
There is one clinical trial.
There is compelling data indicating that there is an excessive inflammatory response in some patients with COVID-19 leading them to develop ARDS that can be severe with a very poor prognosis. Many of these patients require very long mechanical ventilation times to survive, which have led to the collapse of the health system in some regions of the world. The current evidence for the treatment of these severe forms is inconsistent and most scientific societies and governmental or international organizations recommend evaluating treatments with randomized clinical trials. Corticosteroids, being non-specific anti-inflammatory drugs, could shorten the duration of respiratory failure and improve the prognosis. Due to the lack of solid data available regarding this serious disease, our objective is to randomly evaluate the efficacy and safety of the use of dexamethasone, a parenteral corticosteroid approved in Argentina, in patients with ARDS with confirmed respiratory infection due to SARS-CoV-2 (COVID-19). After RECOVERY trial prepublication, low dose (6 mg QD for 10 days) dexamethasone was recommended as the usual care treatment for severe COVID-19. At this time only 3 patients had been included in the trial. Thus, we updated our recommendations for centers and decided to compare two different doses of this glucocorticoid for the treatment of ADRS due to COVID-19.
Description: Days without ventilator support in the first 28 days following randomizationMeasure: Ventilator-free days at 28 days Time: 28 days after randomization
Description: Dead rate within 28 days of randomizationMeasure: 28-days mortality Time: 28 days after randomization
Description: Frequency of ventilator associated pneumonia, blood stream infection or candidemia in the first 28 days following randomizationMeasure: Frequency of nosocomila infections Time: 28 days after randomization
Description: Frequency of positive PCR on nasopharingeal swabMeasure: Viral shedding Time: 28 days after randomization
Description: Change from baseline CPRMeasure: Serum C-reactive Protein variation Time: 10 days after randomization
Description: Variation in SOFA over the first 10 days after randomizationMeasure: SOFA variation Time: 10 days after randomization
Description: Cumulative hours spent on prone positionMeasure: Use of prone position Time: 10 days after randomization
Description: Frequency of delirium at ICU dischargeMeasure: Delirium Time: 28 days after randomization
Description: mMRC score at ICU dischargeMeasure: Muscle weakness Time: 28 days after randomization
Description: Death rate within 90 days of randomizationMeasure: 90-day mortality Time: 90 days after randomization
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports